By development of different encapsulation methods, our lipid-based formulations can deliver both hydrophilic and hydrophobic drugs for cancer, antibacterial, antifungal, immunomodulation, diagnostics, ophtalmica, vaccines, enzymes and genetic elements.

Formulation development

Analytical method development

Process
scaling

Formulation development

We offer the development of encapsulated drugs for all kinds of pharmaceutically active ingredients based on various lipid-based formulations such as:

  • Liposomes
  • Lipid nanoparticles (LNP) for gene therapies (both DNA & RNA)
  • Solid Lipid Nanoparticles (SLN)
  • Nanostructured lipid carriers (NLC)
  • Nanoemulsions
  • Self-emulsifying drug delivery system (SEDDS)

The developed formations are tested in accordance with the QbD (Quality by Design) and ICH guidelines.

Analytical method development

Our analytical services are designed to support our partners development projects, however we will support any standalone analytical project. We also supply tests, starting materials and intermediate products.

SyVento Research and Development Team is located in Cracow, Poland, where the extensive knowledge in biotechnology and nanotechnology meets the deep understanding of the business. 80% of the research team members have PhD in life sciences –mainly biotechnology and chemistry.

SyVento supplies a wide range of equipment, including HPLC (with UV-VIS, DAD, fluorescent, ELSD and MS detector), particle size and zeta-potential measurement devices, viscosity meters, freeze-dryers and spectrometer.

Process scaling

We offer the possibility of scaling the production of formulations based on lipid nanocarriers by transferring solutions developed in the laboratory on a semi-technical and technical scale. Thanks to the extensive equipment base, we are able to perform up-scaling starting from very small batches and up to 50L batches.

Our key projects

Encapsulation of messenger RNA inside lipid nanoparticles

Development of nanocarriers dedicated to various administration routes IM, IV, SC

Encapsulation of hydrofile substance inside liposomes

Development of nanocarriers to reduce toxicity, improve the pharmacokinetic profile

Liposomes as a nano carrier for an inhaled substance

Optimalization of liposomes production in accordance with the GMP standard

Liposome formulation containing a contrast agent

Development of liposome formulation containing a contrast agent

How we support our Partners?

1

Discovery

1A. Building a library of potential formulations

2A. Performing in vitro screening tests, including determination of the potential toxicity of excipients

3A. Selection of auxiliary substances for further research

2

Early preclinical

1B. Determination of the key composition and critical process parameters

2B. Physicochemical characteristics of the formulation along with research on appropriate biological models

3B. Selection of the best formulations for further testing, together with the determination of key test parameters

3

Late preclinical

1C. Refining the manufacturing process

2C. Determination of toxicity, PK, BD, in appropriate biological models

3C. Selection of candidates for the GMP scale up process.

4

Clinical development

1D. Production of a batches for clinical trials

2D. Conducting clinical trials / qualifying supervision over the trial

Why lipid-based formulations?

Advantages of Liposomes

Increase in efficacy and therapeutic index (eg. Actinomycin D)

Act as Scaffold for additional agents

Possibility of several routes of administration (both inhalator and intravenous)

Protect encapsulated drug from metabolic digestion

Increases half life of drug

Biodegradable, bio-compatible & non-immunogenic

Can be made into variety of sizes

Reduced dosage

Reduces systemic toxicity of drug (eg. Taxol, Amphotericin B)

Amphiphilic

Can be targeted to specific tissues or cells

Can carry both lipid & water soluble drugs

Improved pharamacokenetic effects

Can be used as sustained drug release

It helps in reducing the exposure of sensitive tissues to toxic drugs (unmodified Liposomes gather in specific tissues like reticuloendothelial system)

Lipid-based formulations in oncology

Passive (A) and (B) active targeting of nanocarriers. Nanocarriers reach tumours selectively through the leaky vasculature, or in other cases, where the nanocarrier size determines the retention in the tumour tissue. Drugs in the absence of nanocarriers diffuse freely in and out the tumour blood vessels due to their small size, and therefore their effective concentrations in the tumour decrease rapidly. The EPR effect is where drug-loaded nanocarriers cannot diffuse back into the blood stream due to their large size, resulting in progressive accumulation. In active targeting, ligands grafted at the surface of nanocarriers bind to receptors (over)expressed by cancer cells or to angiogenic endothelial cells. Adapted and reproduced with permission

News

Stay up to date with information about our company and products.

Contact us

Let’s collaborate and create quality liposome encapsulated drugs together.

SyVento sp. z o. o.

Chemików 1
32-600 Oświęcim
Poland

Call to us:

+48 33 842 42 18

Send us an email:




    Copyright © 2021 SyventoBioProtect.com. All rights reserved.

    Design and implementation: THE LION

    We use cookies and similar technologies, including for the purposes of: providing services, advertising, statistics. Using the site without changing your browser settings means that they will be placed on your end device. Remember that you can always change these settings.